Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Aug 26, 2021
Finance
Cardior’s €64M B round to push first-in-class heart failure program into Phase II
German company’s goal is disease-modification, a sign of lead investor Inkef Capital’s growing ambition in life sciences.
BioCentury | Dec 31, 2020
Emerging Company Profile
Cardior: targeting microRNAs to treat heart failure
Emerging Company Profile: Cardior is betting on RNA therapies that aim to help dysfunctional hearts pump more efficiently.
BioCentury | Dec 17, 2020
Deals
Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero
First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic
BioCentury | Feb 28, 2020
Distillery Therapeutics
An antisense oligo inhibitor of miR-132 for heart failure
BioCentury | Apr 28, 2016
Finance
Public-Private Partnership Roundup
Highlights of public-private partnerships from 1Q16
Items per page:
1 - 8 of 8